FDA-approved ALTABAX is a topical antibacterial for the treatment of impetigo. It is approved for use in adults and children as young as 9 months old.

5-day b.i.d. Dosing
ALTABAX treats impetigo with 5-day b.i.d. dosing. It provides simplified dosing compared to Bactroban Ointment® (mupirocin ointment), 2% approved for t.i.d. dosing.1 ALTABAX effectively treats impetigo due to methicillin-susceptible strains of Staphylococcus aureus* and Streptococcus pyogenes.

  • Demonstrates superior efficacy in impetigo versus placebo due to S. aureus* and S. pyogenes
  • Latest advance in topical antibacterials since GSK introduced Bactroban Ointment in 1987
  • The only prescription topical antibacterial with simple 5-day b.i.d. dosing

First New Class of Prescription Antibacterials for Topical Use
ALTABAX, a member of the pleuromutilin class, has a novel mode of action. ALTABAX interferes with multiple aspects of protein synthesis. In addition, ALTABAX has a low propensity for resistance in vitro, with no target-specific cross-resistance to other antibacterial classes.2 ALTABAX has demonstrated potent in vitro activity against mupirocin-resistant strains of S. aureus.†3

Generally Well Tolerated, Convenient, and Effective
ALTABAX is approved for use in adults and children as young as 9 months old and is generally well tolerated; 98% of patients experienced no adverse site reactions. In a placebo-controlled trial, ALTABAX demonstrated superior efficacy versus key pathogens. ALTABAX combines efficacy with simple 5-day b.i.d. dosing.

ALTABAX is available in 5-, 10- and 15-gram tubes.

*Methicillin-susceptible isolates only.
†In vitro activity does not necessarily correlate with clinical efficacy.

References:

  1. Bactroban Ointment® (mupirocin ointment), 2% [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2001.
  2. Kosowska-Shick K, Clark K, Credito K, et al. Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes. Antimicrob Agents Chemother. 2006;50:765-769.
  3. Jones RN, Fritsche TR, Sader HS, Ross JE. Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci. Antimicrob Agents Chemother. 2006;50:2583-2586.
Skin Trauma Treatment